Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE). The US FDA has approved this molecule for chronic urticaria.
Keywords: Anaphylaxis; FDA approval; atopic dermatitis; chronic urticaria; monoclonal antibody.